

Journal of Visualized Experiments

Chromatin Immunoprecipitation (ChIP) from Murine Brown Adipose Tissue

--Manuscript Draft--

Article Type:	Invited Methods Article - JoVE Produced Video
Manuscript Number:	JoVE58682R2
Full Title:	Chromatin Immunoprecipitation (ChIP) from Murine Brown Adipose Tissue
Keywords:	ChIP, ChIP-seq, adipose tissue, BAT, transcription, epigenetics
Corresponding Author:	Valentina Perissi Boston University Boston, UNITED STATES
Corresponding Author's Institution:	Boston University
Corresponding Author E-Mail:	vperissi@bu.edu
Order of Authors:	Maria Dafne Cardamone Joseph Orofino Adam Labadorf Valentina Perissi
Additional Information:	
Question	Response
Please indicate whether this article will be Standard Access or Open Access.	Standard Access (US\$2,400)
Please indicate the city, state/province, and country where this article will be filmed . Please do not use abbreviations.	Boston, MA, USA

TITLE:

Chromatin Immunoprecipitation of Murine Brown Adipose Tissue

AUTHORS & AFFILIATIONS:

Maria Dafne Cardamone¹, Joseph Orofino¹, Adam Labadorf², Valentina Perissi¹

¹Biochemistry Department, Boston University School of Medicine, Boston, MA, USA

²Bioinformatic Hub, Boston University, Boston, MA, USA

Corresponding Author:

Valentina Perissi (vperissi@bu.edu)

Email Addresses of Co-authors:

Maria Dafne Cardamone (cardamon@bu.edu)

Joseph Orofino (jorofino@bu.edu)

Adam Labadorf (labadorf@bu.edu)

KEYWORDS:

Chromatin immunoprecipitation, brown adipose tissue, next generation sequencing, mouse, fat

SUMMARY:

Here we describe a protocol for efficient chromatin immunoprecipitation (ChIP) followed by high-throughput DNA sequencing (ChIP-seq) of brown adipose tissue (BAT) isolated from a mouse. This protocol is suitable for both mapping histone modifications and investigating genome-wide localization of non-histone proteins of interest *in vivo*.

ABSTRACT:

Most cellular processes are regulated by transcriptional modulation of specific gene programs. Such modulation is achieved through the combined actions of a wide range of transcription factors (TFs) and cofactors mediating transcriptional activation or repression *via* changes in chromatin structure. Chromatin immunoprecipitation (ChIP) is a useful molecular biology approach for mapping histone modifications and profiling transcription factors/cofactors binding to DNA, thus providing a snapshot of the dynamic nuclear changes occurring during different biological processes.

To study transcriptional regulation in adipose tissue, samples derived from *in vitro* cell cultures of immortalized or primary cell lines are often favored in ChIP assays because of the abundance of starting material and reduced biological variability. However, these models represent a limited snapshot of the actual chromatin state in living organisms. Thus, there is a critical need for optimized protocols to perform ChIP on adipose tissue samples derived from animal models.

Here we describe a protocol for efficient ChIP-seq of both histone modifications and non-histone proteins in brown adipose tissue (BAT) isolated from a mouse. The protocol is optimized for

investigating genome-wide localization of proteins of interest and epigenetic markers in the BAT, which is a morphologically and physiologically distinct tissue amongst fat depots.

INTRODUCTION:

While white adipose tissue (WAT) is specialized for energy storage, brown adipose tissue (BAT) dissipates energy in the form of heat due to its ability to convert carbohydrates and lipids into thermal energy *via* mitochondrial uncoupling¹. Because of this specialized function, the BAT depot is required for maintenance of body temperature in physiological conditions and in response to cold exposure. While gene expression changes during BAT differentiation and upon thermogenic stress have been extensively studied *in vivo* and *in vitro*, the molecular mechanisms underlying these changes have been mostly dissected in immortalized cell lines and primary pre-adipocytes, with the exception of several *in vivo* studies²⁻⁵.

Regulation of specific gene expression programs through transcriptional regulation is achieved by coordinated changes in chromatin structure *via* various transcription factors and co-factors actions. Chromatin immunoprecipitation (ChIP) is a valuable molecular biology approach for investigating the recruitment of these factors to DNA and for profiling the associated changes in the chromatin landscape. Key factors for the success of ChIP experiments include optimizations of crosslinking conditions and chromatin shearing consistency throughout different samples, availability of adequate starting material, and, most notably, quality of the antibodies. When performing ChIP from whole tissues, it is also important to consider heterogeneity of the samples and optimize the protocol to improve efficiency of nuclei isolation, with the latter being a particularly sensitive step when working with adipose tissue due to the elevated lipid content. In fact, molecular isolation techniques from whole adipose depots are complicated by the presence of high levels of triglycerides, and protocols must be optimized to increase the amount of chromatin isolation. Finally, when high-throughput sequencing is performed after ChIP-DNA isolation, the sequencing depth is critical for determining the number of peaks that are confidently detected.

Here, we refer to the working standards and general guidelines for ChIP-seq experiments recommended by the ENCODE and modENCODE consortia⁶ for best practices, and we focus on a step-by-step description of a protocol optimized for ChIP-seq from BAT. The described protocol allows for efficient isolation of chromatin from adipose tissue to perform genome-wide sequencing for DNA-binding factors with well-defined peaks as well as histone marks with more diffuse signals.

PROTOCOL:

The animal handling steps of the protocol have been approved by Boston University's Institutional Animal Care and Use Committee (IACUC).

1. Day 1: Dissection and Preparation of BAT for Chromatin Immunoprecipitation (ChIP)

1.1. Euthanize mice using a carbon dioxide (CO₂) chamber, and perform the dissection immediately afterwards. Spray mouse fur with 70% ethanol before incision. Place the mouse with

its back facing up, then cut open the skin along the neck. Locate the BAT directly under the skin between the shoulders (interscapular; it appears as two lobes, butterfly-shaped, with a thin layer of white fat that needs to be carefully removed⁷).

Note: For a three-month-old C57BL/6J mouse that is fed a regular chow diet (mouse weight at this age ranges between 27 and 30 g), each BAT lobe is approximately 1 cm long. The total weight of the BAT depot is approximately 0.15 g in both male and female mice.

1.2. Use 1 BAT pad for 3 ChIPs. Multiple BAT pads can be simultaneously processed until sonication.

1.3. Crosslink each BAT pad in 10 mL of phosphate-buffered saline (PBS) containing 1% formaldehyde for 15 min rotating at 150 rpm at room temperature (RT).

1.4. Quench crosslinking by adding 2.5 M glycine to a final concentration of 125 mM for 5 min, rotating at 150 rpm at RT.

1.5. Transfer the BAT pad to 500 μ L of hypotonic lysis buffer (10 mM HEPES, 1.5 mM $MgCl_2$, 10 mM KCl, 0.5 mM DTT, 0.2 mM PMSF) and add 2 stainless steel beads (size: 3.2 mm diameter, see **Table of Materials**) for each BAT pad. Use a bead-based tissue homogenizer (see **Table of Materials**) to shred the tissue.

1.6. Start with 5 min at max power. If needed, extend the time until the tissue is homogenized and single cells are separated. Transfer the samples into a new tube and centrifuge at 4 °C at 16,000 x g for 10 min.

1.7. After centrifugation, transfer the supernatant into a new tube and keep the cell pellet on ice. Centrifuge the supernatant at 4 °C at 16,000 x g for 10 min to prevent loss of floating cells. Discard the final supernatant and resuspend both cell pellets together in 300 μ L of SDS lysis buffer (SDS 1%; EDTA 10 mM; Tris-HCl pH 8, 50 mM) with 1x protease inhibitor (see **Table of Materials**). Incubate on ice for 10 min.

1.8. Sonicate the lysates to generate DNA fragments 200-500 base pairs long. After sonication, remove debris by centrifugation for 10 min at 16,000 x g at 4 °C and check the success of sonication *via* DNA electrophoresis on a 1% agarose gel. For a medium-size gel, run at 120 V; a good separation is achieved after 45 min.

Note: Sonication optimization may be required to achieve proper size of fragments. With the chosen sonicator (see **Table of Materials**), this requires 2 times at 320 W output power and 20 KHz frequency for 10 min, using cycles of 30 s on/30 s off.

1.9. Dilute the supernatant fraction 10-fold (final volume is 3 mL for each BAT pad) in ChIP dilution buffer (SDS 0.01%; Triton 1.1%; EDTA 1.2 mM; Tris-HCl pH 8, 16.7 mM; NaCl 167 mM)

with 1x protease inhibitor. Keep aside 1% of this chromatin solution (equal to 30 μ L for 3 mL) as the ChIP input. Keep the inputs overnight at 4 °C (until step 2.4).

Note: The above fraction will provide the input reference for relative quantification of immunoprecipitated material compared to the amount of DNA present in each sample prior to immunoprecipitation.

1.10. Add the ChIP antibody (see **Table of Materials** for the antibodies used here as an example) to 1 mL of chromatin solution and incubate overnight at 4 °C with rotation. Perform parallel immunoprecipitation with corresponding pre-immune IgG, if available, or normal IgG of the same species (*e.g.*, regular rabbit IgG if the antibody is produced in a rabbit). Alternatively, save 1 mL of chromatin solution for a no-antibody control.

Note: The optimal amount of antibody should be determined experimentally for each new antibody, if the antibody concentration is not known. Otherwise, 2-5 μ g of antibody is a reasonable starting amount to use. Use ChIP-grade antibodies whenever possible, or antibodies that have been validated for immunoprecipitation.

2. Day 2: Collection of the Immune Complexes

2.1 Add 50 μ L of Protein A Agarose 50% slurry to the immune complexes and incubate for 1 h at 4 °C with rotation at 150 rpm.

2.2 Pellet the beads by centrifugation for 1 min at 100 x g at 4 °C. Perform sequential washes of the beads with buffers of increasing stringency.

2.2.1 First, wash with low-salt wash buffer (150 mM NaCl; Tris-HCl pH 8, 20 mM; EDTA 2 mM; Triton-X 1%; SDS 0.1%), then with high-salt wash buffer (500 mM NaCl; Tris-HCl pH 8, 20 mM; EDTA 2 mM, Triton-X1%; SDS 0.1%), then with LiCl wash (0.25 M LiCl; Tris-HCl pH 8, 10 mM; EDTA 1 mM; Igepal 1%; deoxicholate 1%), and finally with 1x TE (Tris-HCl pH 8, 10 mM; EDTA).

2.2.2 Perform all washes on 0.45 μ m PVDF centrifugal filter columns (**Table of Materials**) by first transferring the beads in the columns using 500 μ L of low-salt wash buffer. Pellet the beads in the columns for 3 min at 2,500 x g. Discard the flow-through and repeat 1 time for all the wash buffers listed in step 2.2.1.

2.3 After the washes are completed, elute the immune complexes by adding 300 μ L of elution buffer 1% SDS, 0.1 M NaHCO₃) to the pelleted beads in the columns. Incubate at RT for 30 min on a shaker at 400 rpm. Collect the eluate by spinning down columns for 3 min at 2,500 x g in a fresh tube.

2.4 Reverse the crosslinks by incubating the eluate and inputs collected in step 1.9 at 65 °C overnight.

3. Day 3: Recovery of DNA with Phenol/Chloroform Extraction

3.1 Add 300 µL of phenol:chloroform:IAA, 1:1 to the eluate and inputs. Vortex for 10 s.

3.2 Spin at 4 °C for 15 min at 21,000 x g. Transfer the supernatant to a fresh tube. Add 3 µL of glycogen, 30 µL of 3 M sodium acetate, and 750 µL of cold 100% ethanol. Vortex for 10 s. Store at -80 °C for 2 h.

3.3 Spin down at 21,000 x g at 4 °C for 20 min, keep the pellet, and discard the supernatant. Wash pellet with 1 mL of cold 70% EtOH, then spin down at 21,000 x g at 4 °C for 5 min. Discard the supernatant and air-dry the pellet.

3.4 Resuspend the pellet in 70 µL of DNase-free water.

3.5 Proceed to step 4 for testing chromatin occupancy on specific genomic regions by quantitative polymerase chain reaction (qPCR) or to step 5 to prepare samples for sequencing.

4. Analysis of ChIP using qPCR (Single/Multiple Genes Readout)

4.1. Dilute the input DNA from step 3.4 to generate a standard reference curve. Serial dilutions of 1/10, 1/100, and 1/1000 are usually sufficient to capture the linear range, but further dilutions may be required for more concentrated samples.

4.2. For each primer pair (here, we have used primers targeting NDUFV1 and TOMM20 promoters), prepare two sets of qPCR reactions: one using the diluted input samples from step 4.1, and a second with the DNA samples isolated by immunoprecipitation from step 3.4. Perform each reaction in triplicate.

Note: Reactions can be set up in parallel for multiple genes using 96- or 384-well plates.

4.3. Set up a reaction volume of 10 µL per well with 5 µL of 2x PCR mix (**Table of Materials**), 1 µL of primer mix (1 µM forward primer and 1 µM reverse primer), and 4 µL of DNA from ChIP (or the input control).

4.4. Briefly spin down the plate.

4.5. Run the qPCR reactions on a real-time PCR system using the protocol recommended by the manufacturer for reagent detection (**Table of Materials**). Here we have used the following conditions: 1) 1s at 95°C for 1 cycle; 2) 1 s at 95 °C followed by 20 s at 60 °C for 45 cycles; 3) 15 s at 95 °C followed by 60 s at 60 °C followed by 15 s at 95 °C for 1 cycle.

Note: Check the dissociation curve: the presence of one peak in the thermal dissociation plot suggests a single amplicon is generated from the PCR reaction. If more than one peak is

visualized, this is potentially indicative of multiple, non-specific amplicons; in which case, we recommend the design of alternative primer pairs.

4.6. Determine the linear phase of exponential amplification of the PCR reaction for each primer set by calculating the standard curve using the series of diluted genomic DNA in step 4.1. according to the Ct (cycle threshold) value.

4.7. If the Ct value of DNA from ChIP and input control are within the linear range of Ct value, calculate the enrichment of DNA from ChIP relative to the input, according to the dilution factor of DNA from ChIP and input control in step 4.1.

5. Amplification of DNA from ChIP for High-Throughput Sequencing (Genome-Wide Readout)

Note: This step can be outsourced to an academic core facility or commercial sequencing company when sequencing capabilities are not available in-house.

5.1. Prepare a DNA library from the extracted DNA with an appropriate ChIP library preparation kit (see **Table of Materials**) following the manufacturer's instructions.

5.2. Sequence the library on a high-throughput sequencing system, using 50 bp single-end as readout (see **Table of Materials**).

Note: According to ChIP-seq guidelines suggested by ENCODE⁶, a minimum of 10 million reads is recommended for mammalian genomes.

6. Raw Data Analysis

6.1. Perform quality control on raw sequencing reads using FastQC⁸.

Note: Common sequencing quality metrics include per base sequence quality, per base sequence content, per sequence GC content, sequence length, and sequence duplication levels. Generally, a read quality score of Q > 30 across each base position is indicative of high-quality sequencing results. The distribution of GC content across all reads should roughly resemble a normal distribution, with a peak centered around the species' actual genomic GC content percentage.

6.2. Remove any sequencing adapter contamination and low-quality reads through the read trimming utility Trimmomatic⁹.

Note: The implemented default parameters specify the removal of platform dependent adapters, removal of leading and trailing low-quality bases, and use of a 4-base wide sliding window to trim reads when the average quality per base drops below a specified threshold.

6.3. Align processed reads to the mouse MM10 reference genome¹⁰ with the Bowtie2 aligner¹¹ using default parameters.

6.4. Filter aligned reads by removing those with a Bowtie2 mapping quality score (MAPQ) of less than 10 using Samtools¹².

6.5. Determine various post-alignment quality metrics such as percent reads mapped, strand cross-correlation, cumulative read coverage, and sample replicate reproducibility.

Note: Various packages including SPP¹³, ChIPqc¹⁴, and Deeptools¹⁵ are available to calculate these quality metrics.

6.6. Perform peak calling analysis with an input control or appropriate KO sample using the MACS algorithm (MACS2)¹⁶ with default parameters.

6.7. Remove any called peaks that overlap with known blacklisted regions¹⁷ from the mm10 annotation using Bedtools¹⁸.

Note: Blacklisted regions are areas in the genome that have been shown to have high signal or read counts independent of cell line or sequencing technique. These regions display artificially high artifact signals in certain regions of the genome that can be filtered out of functional genomic sequencing experiments. All replicates should be processed independently through the pipeline and may then be used for irreproducibility discovery rate (IDR). IDR is employed to measure the reproducibility of findings between replicates through the method as described by Li, Brown, Huang, and Bickel^{19,20}. The IDR method quantitatively assesses consistency between replicates and is recommended by ENCODE and modENCODE as part of their ChIP-seq guidelines.

6.8. Use statistically significant peaks for various downstream analyses such as gene ontology^{21,22}, enrichment, or motif analysis²³.

REPRESENTATIVE RESULTS:

[Place Figure 1 here]

Examples of ChIP-qPCR using BAT isolated from WT or GPS2-AKO mice are shown in **Figure 1**². Having found that GPS2 was required for the expression of nuclear-encoded mitochondrial genes in different cell lines², we tested the recruitment of GPS2 on two specific nuclear-encoded mitochondrial genes, *NDUFV1* and *TOMM20*, in BAT from mice as an example of a tissue highly enriched in mitochondria. We first compared GPS2 promoter occupancy in GPS2-AKO mice and wild-type littermates, observing an expected decrease in GPS2 binding on selective target genes in the BAT from GPS2-AKO mice. Using the protocol described here, we also recorded increased binding of RNA polymerase 2 (Pol2) and the repressive histone mark H3K9me3 in the BAT from GPS2-AKO mice as compared to wild-type littermates. For all antibodies, the binding was significant as compared to the background signal observed in the IgG control sample. These results confirm the recruitment of GPS2 on selected nuclear-encoded mitochondrial genes and show that GPS2 is required for preventing the accumulation of H3K9me3, and thus required for

the stalling of Pol2 transcriptional activity on target promoters. See the **Table of Materials** for more details on the antibodies and the original publication for additional data and more comprehensive discussion of these results².

[Place Figure 2 here]

In **Figure 2**, sequencing quality scores are shown at a per base level, and reads may be further processed by trimming any residual adapter contamination and removing reads where the average quality score across a sliding window falls below a specified threshold. Also shown is the GC content distribution across reads after adapter removal and read trimming. Sequence quality and GC content distribution are two widely used metrics to evaluate next generation sequencing data before computational analyses are performed. These results demonstrate that the protocol produces a sufficient amount of high-quality chromatin isolated from BAT that is compatible with downstream next-generation sequencing technologies.

[Place Figure 3 here]

Shown in **Figure 3** are bigWig tracks of the WT and GPS2-AKO aligned BAM files normalized to 1x depth (reads per genome coverage) as implemented in deepTools. Shown is the presence of a statistically significant peak located in the promoter region of the mitochondrial gene *Slc25a25*. The normalized tracks allow visualization of the enrichment of reads corresponding to the called peak and the reduction of reads at this location in the BAT of GPS2-AKO mice relative to wild-type littermates.

FIGURE LEGENDS:

Figure 1: ChIP validation by qPCR. ChIP-qPCR analysis of representative GPS2 target genes *NDUFV1* (left) and *TOMM20* (right) in the BAT of WT and GPS2-AKO mice, showing relative changes in the level of H3K9 methylation and GPS2 and Pol2 binding. The bar graphs represent the sample mean of 3 replicates with *p < 0.05 and **p < 0.01 as calculated with Student's t-test. This figure is modified from Cardamone *et al.*².

Figure 2: Plot of quality scores from raw sequencing reads isolated from BAT. (A) Quality scores reflect a prediction of the probability of an error during base-calling. It is commonly expressed as an integer value, $Q = -10\log_{10}(P)$, in which P is the probability of an error in base-calling. Shown above is a per base sequence quality plot generated by FastQC based on raw, unprocessed sequencing reads generated from BAT. (B) GC content distribution of reads after adapter removal and read trimming from BAT samples. GC content should roughly resemble a normal distribution with a peak centered around the species' actual fraction of GC genomic content.

Figure 3: Normalized bigwig files generated from ChIP-seq data from the BAT of WT and GPS2-AKO mice. This figure shows the normalized read coverage along the *Slc25a25* gene locus with a significantly called peak in the promoter region. GPS2 was shown to regulate the expression of nuclear-encoded mitochondrial genes by altering the chromatin state of target gene promoters.

These results display the visualization of a significantly called peak on a representative nuclear-encoded mitochondrial gene.

DISCUSSION:

The protocol described here represents a valuable tool for performing ChIP from murine tissues, specifically optimized for brown adipose tissue. One of the greater challenges in performing ChIP from tissue is recovering a sufficient number of cells during sample preparation. Shearing the BAT using a tissue homogenizer blender coupled with stainless steel beads instead of a canonical glass pestle significantly reduces the number of cells lost due to unbroken tissue. Moreover, homogenizing the tissue directly in a hypotonic buffer helps the release of lipids that can then be easily separated and removed from the nuclei *via* high-speed centrifugation.

Proper sonication is also critical for performing consistent and reproducible ChIP assays. The use of a water bath ultra-sonicator allows for the simultaneous processing of multiple samples, thus improving reproducibility of chromatin shearing and reducing the risk of sample cross-contamination. In addition, use of a temperature-controlled sonication system reduces overheating of the samples, which should be avoided to prevent sample degradation and loss of epitope recognition by the antibody (see **Table of Materials** for details).

Another challenging step is the recovery of immunoprecipitated complexes. Magnetic beads are often preferred for this step because they allow for faster and more effective washes when used together with a magnetic rack. However, they have a lower rate of DNA recovery compared to Protein A Agarose, which can be a serious limitation when working with small amount of starting material. We find that the combination of Protein A Agarose slurry with PVDF 0.45 μ m centrifugal filter columns is a great solution to achieve maximum DNA yield with minimal washing time and higher reproducibility.

Regarding the DNA isolation, plenty of columns-based DNA isolation kits can be used. In our experience, one limitation of this approach is the capacity of the columns to have an effect on the yield of DNA recovery. To overcome the problem, we prefer using a more traditional method as phenol/chloroform for DNA extraction.

The listed ChIP-seq pipeline incorporates a number of widely accepted tools and utilities for next generation sequencing experiments. Briefly, the reads are subjected to basic quality control using FastQC and Trimmomatic, then aligned to the mouse MM10 genome using Bowtie2. Surviving reads are filtered by mapping quality before being used for peak calling through the MACS2 algorithm. However, it should be noted that other available and validated tools may also be used depending on the nature of the experiment and data being generated. The use of any customized parameters during pre-processing, alignment, or peak calling may also be appropriate.


REFERENCES:

1. Cannon, B., Nedergaard, J. Brown adipose tissue: function and physiological significance. *Physiological Reviews*. (2004).


2. Cardamone, M. D., *et al.* Mitochondrial Retrograde Signaling in Mammals Is Mediated by the Transcriptional Cofactor GPS2 *via* Direct Mitochondria-to-Nucleus Translocation. *Molecular Cell*. **69**, (2018).
3. Emmett, M. J., *et al.* Histone deacetylase 3 prepares brown adipose tissue for acute thermogenic challenge. *Nature*. (2017).
4. Harms, M. J., *et al.* PRDM16 binds MED1 and controls chromatin architecture to determine a brown fat transcriptional program. *Genes & Development*. (2015).
5. Shapira, S. N., *et al.* EBF2 transcriptionally regulates brown adipogenesis *via* the histone reader DPFF3 and the BAF chromatin remodeling complex. *Genes & Development*. (2017).
6. Landt, S. G., *et al.* ChIP-seq guidelines and practices of the ENCODE and modENCODE consortia. *Genome Research*. **22**, 1813–1831 (2012).
7. Liisberg Aune, U., Ruiz, L., Kajimura, S. Isolation and Differentiation of Stromal Vascular Cells to Beige/Brite Cells. *Journal of Visualized Experiments*. e50191 (2013).
8. Andrews, S. FastQC: a quality control tool for high throughput sequence data. Available online at: <http://www.bioinformatics.babraham.ac.uk/projects/fastqc>. (2010).
9. Bolger, A. M., Lohse, M., Usadel, B. Trimmomatic: a flexible trimmer for Illumina sequence data. *Bioinformatics*. **30**, 2114–20 (2014).
10. <https://genome.ucsc.edu/cgi-bin/hgGateway?db=mm10>
11. Langmead, B., Salzberg, S. L. Fast gapped-read alignment with Bowtie 2. *Nature Methods*. **9**, 357–359 (2012).
12. Li, H., *et al.* The Sequence alignment/map (SAM) format and SAMtools. *Bioinformatics*. **25** (16), 2078–9 (2009).
13. Kharchenko, P. V., Tolstorukov, M. Y., Park, P. J. Design and analysis of ChIP-seq experiments for DNA-binding proteins.
14. Carroll, T. S., Liang, Z., Salama, R., Stark, R., de Santiago, I. Impact of artifact removal on ChIP quality metrics in ChIP-seq and ChIP-exo data. *Frontiers in Genetics*. **5**, 75 (2014).
15. Ramírez, F., *et al.* deepTools2: A next Generation Web Server for Deep-Sequencing Data Analysis. *Nucleic Acids Research*. (2016).
16. Zhang, Y., *et al.* Model-based Analysis of ChIP-Seq (MACS). *Genome Biology*. **9**, R137 (2008).
17. ENCODE Project Consortium. An integrated encyclopedia of DNA elements in the human genome. *Nature*. **489** (7414), 57–74 (2012).
18. Quinlan, A. R., Hall, I. M. BEDTools: a flexible suite of utilities for comparing genomic features. *Bioinformatics*. **26**, 841–842 (2010).
19. Li, Q., Brown, J. B., Huang, H., Bickel, P. J. Measuring reproducibility of high-throughput experiments. *Annals of Applied Statistics*. **5** (3), 1752–1779 (2011).
20. Irreproducible Discovery Rate (IDR) <https://github.com/nboley/idr> (2018)
21. The Gene Ontology Consortium. Expansion of the Gene Ontology Knowledgebase and Resources. *Nucleic Acids Research*. **45**, D331–D338 (2017).
22. Ashburner, M., *et al.* Gene Ontology: tool for the unification of biology. *Nature Genetics*. **25**, 25–29 (2000).
23. Boeva, V. Analysis of Genomic Sequence Motifs for Deciphering Transcription Factor Binding and Transcriptional Regulation in Eukaryotic Cells. *Frontiers in Genetics*. **7**, 24 (2016).

437
438
439
440


NDUFV1 promoter




TOMM20 promoter




A Quality Score across all bases



B GS distributuion over all sequence





Name of the Buffer	Reagent	Final Concentration
Hypotonic Lysis	HEPES	10 mM
	MgCl ₂	1.5 mM
	KCl	10 mM
	DTT	.5 mM
	PMSF	.2 mM
	PIC	1 X
SDS Lysis	SDS	1%
	EDTA	10mM
	Tris-HCl pH8	50mM
ChIP Dilutin	SDS	0.01%
	Triton	1.10%
	EDTA	1.2mM
	Tris-HCl pH8	16.7mM
	NaCl	167 mM
Low Salt	SDS	0.10%
	Triton X	1%
	EDTA	2mM
	Tris-HCl pH8	20mM
	NaCl	150mM
High Salt	SDS	0.10%
	Triton	1%
	EDTA	2mM
	Tris-HCl pH8	20mM
	NaCl	500mM
LiCl	LiCl	0.25M
	NP40	1%
	Deoxycholate	1%
	EDTA	1mM
	Tris-HCl pH8	10mM
TE	EDTA	1mM
	Tris-HCl pH8	10mM
Elution	SDS	1%
	NaHCO ₃	0,1M

Name of Material/ Equipment	Company	Catalog Number	Comments/Description
Bullet Blender Tissue Homogenizer	Next Advence	BBX24	Rabbit polyclonal, Ct antibody (Cardamone et al., Mol Cell
Stainless Steel Beads 3.2mm Diameter	Next Advence	SSB32	
Bioruptor Sonicator	Diagenode		
1.5 ml Micro Tube TPX Plastic	Diagenode	C30010010-5	
Complete-Protease inhibitor	Roche	11836145001	
Protein A Agarose Slurry	Invitrogen	101041	
GPS2 antibody	In house		
Pol2 antibody	Diagenode	C15100055	
h3K9me3 antibody	Millipore	05-1242	
Fast Syber Green Master Mix	Aplied Biosytem	4385612	
ViiA7	Aplied Biosytem		
TruSeq ChIP Library Preparation Kit	Illumina	IP-202-1012	
HiSeq 2000	Illumina		

2018)



1 Alewife Center #200
Cambridge, MA 02140
tel. 617.945.9051
www.jove.com

ARTICLE AND VIDEO LICENSE AGREEMENT

Title of Article:	Chromatin Immunoprecipitation (ChIP) from Murine Brown Adipose Tissue
Author(s):	Maria Dafne Cardamone ¹ , Joseph Orofino ¹ , Adam Labadorf ² , Valentina Perissi ¹

Item 1: The Author elects to have the Materials be made available (as described at <http://www.jove.com/publish>) via:

☐

Standard Access

☒

Open Access

Item 2: Please select one of the following items:

☒

The Author is **NOT** a United States government employee.

☐

The Author is a United States government employee and the Materials were prepared in the course of his or her duties as a United States government employee.

☐

The Author is a United States government employee but the Materials were NOT prepared in the course of his or her duties as a United States government employee.

ARTICLE AND VIDEO LICENSE AGREEMENT

1. **Defined Terms.** As used in this Article and Video License Agreement, the following terms shall have the following meanings: **"Agreement"** means this Article and Video License Agreement; **"Article"** means the article specified on the last page of this Agreement, including any associated materials such as texts, figures, tables, artwork, abstracts, or summaries contained therein; **"Author"** means the author who is a signatory to this Agreement; **"Collective Work"** means a work, such as a periodical issue, anthology or encyclopedia, in which the Materials in their entirety in unmodified form, along with a number of other contributions, constituting separate and independent works in themselves, are assembled into a collective whole; **"CRC License"** means the Creative Commons Attribution-Non Commercial-No Derivs 3.0 Unported Agreement, the terms and conditions of which can be found at: <http://creativecommons.org/licenses/by-nc-nd/3.0/legalcode>; **"Derivative Work"** means a work based upon the Materials or upon the Materials and other pre-existing works, such as a translation, musical arrangement, dramatization, fictionalization, motion picture version, sound recording, art reproduction, abridgment, condensation, or any other form in which the Materials may be recast, transformed, or adapted; **"Institution"** means the institution, listed on the last page of this Agreement, by which the Author was employed at the time of the creation of the Materials; **"JoVE"** means MyJoVE Corporation, a Massachusetts corporation and the publisher of The Journal of Visualized Experiments; **"Materials"** means the Article and / or the Video; **"Parties"** means the Author and JoVE; **"Video"** means any video(s) made by the Author, alone or in conjunction with any other parties, or by JoVE or its affiliates or agents, individually or in collaboration with the Author or any other parties, incorporating all or any portion

of the Article, and in which the Author may or may not appear.

2. **Background.** The Author, who is the author of the Article, in order to ensure the dissemination and protection of the Article, desires to have the JoVE publish the Article and create and transmit videos based on the Article. In furtherance of such goals, the Parties desire to memorialize in this Agreement the respective rights of each Party in and to the Article and the Video.

3. **Grant of Rights in Article.** In consideration of JoVE agreeing to publish the Article, the Author hereby grants to JoVE, subject to **Sections 4** and **7** below, the exclusive, royalty-free, perpetual (for the full term of copyright in the Article, including any extensions thereto) license (a) to publish, reproduce, distribute, display and store the Article in all forms, formats and media whether now known or hereafter developed (including without limitation in print, digital and electronic form) throughout the world, (b) to translate the Article into other languages, create adaptations, summaries or extracts of the Article or other Derivative Works (including, without limitation, the Video) or Collective Works based on all or any portion of the Article and exercise all of the rights set forth in (a) above in such translations, adaptations, summaries, extracts, Derivative Works or Collective Works and (c) to license others to do any or all of the above. The foregoing rights may be exercised in all media and formats, whether now known or hereafter devised, and include the right to make such modifications as are technically necessary to exercise the rights in other media and formats. If the "Open Access" box has been checked in **Item 1** above, JoVE and the Author hereby grant to the public all such rights in the Article as provided in, but subject to all limitations and requirements set forth in, the CRC License.

ARTICLE AND VIDEO LICENSE AGREEMENT

4. **Retention of Rights in Article.** Notwithstanding the exclusive license granted to JoVE in **Section 3** above, the Author shall, with respect to the Article, retain the non-exclusive right to use all or part of the Article for the non-commercial purpose of giving lectures, presentations or teaching classes, and to post a copy of the Article on the Institution's website or the Author's personal website, in each case provided that a link to the Article on the JoVE website is provided and notice of JoVE's copyright in the Article is included. All non-copyright intellectual property rights in and to the Article, such as patent rights, shall remain with the Author.

5. **Grant of Rights in Video – Standard Access.** This **Section 5** applies if the "Standard Access" box has been checked in **Item 1** above or if no box has been checked in **Item 1** above. In consideration of JoVE agreeing to produce, display or otherwise assist with the Video, the Author hereby acknowledges and agrees that, Subject to **Section 7** below, JoVE is and shall be the sole and exclusive owner of all rights of any nature, including, without limitation, all copyrights, in and to the Video. To the extent that, by law, the Author is deemed, now or at any time in the future, to have any rights of any nature in or to the Video, the Author hereby disclaims all such rights and transfers all such rights to JoVE.

6. **Grant of Rights in Video – Open Access.** This **Section 6** applies only if the "Open Access" box has been checked in **Item 1** above. In consideration of JoVE agreeing to produce, display or otherwise assist with the Video, the Author hereby grants to JoVE, subject to **Section 7** below, the exclusive, royalty-free, perpetual (for the full term of copyright in the Article, including any extensions thereto) license (a) to publish, reproduce, distribute, display and store the Video in all forms, formats and media whether now known or hereafter developed (including without limitation in print, digital and electronic form) throughout the world, (b) to translate the Video into other languages, create adaptations, summaries or extracts of the Video or other Derivative Works or Collective Works based on all or any portion of the Video and exercise all of the rights set forth in (a) above in such translations, adaptations, summaries, extracts, Derivative Works or Collective Works and (c) to license others to do any or all of the above. The foregoing rights may be exercised in all media and formats, whether now known or hereafter devised, and include the right to make such modifications as are technically necessary to exercise the rights in other media and formats. For any Video to which this **Section 6** is applicable, JoVE and the Author hereby grant to the public all such rights in the Video as provided in, but subject to all limitations and requirements set forth in, the CRC License.

7. **Government Employees.** If the Author is a United States government employee and the Article was prepared in the course of his or her duties as a United States government employee, as indicated in **Item 2** above, and any of the licenses or grants granted by the Author hereunder exceed the scope of the 17 U.S.C. 403, then the rights granted hereunder shall be limited to the maximum

rights permitted under such statute. In such case, all provisions contained herein that are not in conflict with such statute shall remain in full force and effect, and all provisions contained herein that do so conflict shall be deemed to be amended so as to provide to JoVE the maximum rights permissible within such statute.

8. **Protection of the Work.** The Author(s) authorize JoVE to take steps in the Author(s) name and on their behalf if JoVE believes some third party could be infringing or might infringe the copyright of either the Author's Article and/or Video.

9. **Likeness, Privacy, Personality.** The Author hereby grants JoVE the right to use the Author's name, voice, likeness, picture, photograph, image, biography and performance in any way, commercial or otherwise, in connection with the Materials and the sale, promotion and distribution thereof. The Author hereby waives any and all rights he or she may have, relating to his or her appearance in the Video or otherwise relating to the Materials, under all applicable privacy, likeness, personality or similar laws.

10. **Author Warranties.** The Author represents and warrants that the Article is original, that it has not been published, that the copyright interest is owned by the Author (or, if more than one author is listed at the beginning of this Agreement, by such authors collectively) and has not been assigned, licensed, or otherwise transferred to any other party. The Author represents and warrants that the author(s) listed at the top of this Agreement are the only authors of the Materials. If more than one author is listed at the top of this Agreement and if any such author has not entered into a separate Article and Video License Agreement with JoVE relating to the Materials, the Author represents and warrants that the Author has been authorized by each of the other such authors to execute this Agreement on his or her behalf and to bind him or her with respect to the terms of this Agreement as if each of them had been a party hereto as an Author. The Author warrants that the use, reproduction, distribution, public or private performance or display, and/or modification of all or any portion of the Materials does not and will not violate, infringe and/or misappropriate the patent, trademark, intellectual property or other rights of any third party. The Author represents and warrants that it has and will continue to comply with all government, institutional and other regulations, including, without limitation all institutional, laboratory, hospital, ethical, human and animal treatment, privacy, and all other rules, regulations, laws, procedures or guidelines, applicable to the Materials, and that all research involving human and animal subjects has been approved by the Author's relevant institutional review board.

11. **JoVE Discretion.** If the Author requests the assistance of JoVE in producing the Video in the Author's facility, the Author shall ensure that the presence of JoVE employees, agents or independent contractors is in accordance with the relevant regulations of the Author's institution. If more than one author is listed at the beginning of this Agreement, JoVE may, in its sole

ARTICLE AND VIDEO LICENSE AGREEMENT

discretion, elect not take any action with respect to the Article until such time as it has received complete, executed Article and Video License Agreements from each such author. JoVE reserves the right, in its absolute and sole discretion and without giving any reason therefore, to accept or decline any work submitted to JoVE. JoVE and its employees, agents and independent contractors shall have full, unfettered access to the facilities of the Author or of the Author's institution as necessary to make the Video, whether actually published or not. JoVE has sole discretion as to the method of making and publishing the Materials, including, without limitation, to all decisions regarding editing, lighting, filming, timing of publication, if any, length, quality, content and the like.

12. **Indemnification.** The Author agrees to indemnify JoVE and/or its successors and assigns from and against any and all claims, costs, and expenses, including attorney's fees, arising out of any breach of any warranty or other representations contained herein. The Author further agrees to indemnify and hold harmless JoVE from and against any and all claims, costs, and expenses, including attorney's fees, resulting from the breach by the Author of any representation or warranty contained herein or from allegations or instances of violation of intellectual property rights, damage to the Author's or the Author's institution's facilities, fraud, libel, defamation, research, equipment, experiments, property damage, personal injury, violations of institutional, laboratory, hospital, ethical, human and animal treatment, privacy or other rules, regulations, laws, procedures or guidelines, liabilities and other losses or damages related in any way to the submission of work to JoVE, making of videos by JoVE, or publication in JoVE or elsewhere by JoVE. The Author shall be responsible for, and shall hold JoVE harmless from, damages caused by lack of sterilization, lack of cleanliness or by contamination due to

the making of a video by JoVE its employees, agents or independent contractors. All sterilization, cleanliness or decontamination procedures shall be solely the responsibility of the Author and shall be undertaken at the Author's expense. All indemnifications provided herein shall include JoVE's attorney's fees and costs related to said losses or damages. Such indemnification and holding harmless shall include such losses or damages incurred by, or in connection with, acts or omissions of JoVE, its employees, agents or independent contractors.

13. **Fees.** To cover the cost incurred for publication, JoVE must receive payment before production and publication the Materials. Payment is due in 21 days of invoice. Should the Materials not be published due to an editorial or production decision, these funds will be returned to the Author. Withdrawal by the Author of any submitted Materials after final peer review approval will result in a US\$1,200 fee to cover pre-production expenses incurred by JoVE. If payment is not received by the completion of filming, production and publication of the Materials will be suspended until payment is received.

14. **Transfer, Governing Law.** This Agreement may be assigned by JoVE and shall inure to the benefits of any of JoVE's successors and assignees. This Agreement shall be governed and construed by the internal laws of the Commonwealth of Massachusetts without giving effect to any conflict of law provision thereunder. This Agreement may be executed in counterparts, each of which shall be deemed an original, but all of which together shall be deemed to be one and the same agreement. A signed copy of this Agreement delivered by facsimile, e-mail or other means of electronic transmission shall be deemed to have the same legal effect as delivery of an original signed copy of this Agreement.

A signed copy of this document must be sent with all new submissions. Only one Agreement is required per submission.

CORRESPONDING AUTHOR

Name:	Valentina Perissi		
Department:	Biochemistry		
Institution:	Boston University		
Title:	Associate Professor		
Signature:	<i>Valentina Perissi</i>	Date:	06/26/2018

Please submit a **signed** and **dated** copy of this license by one of the following three methods:

1. Upload an electronic version on the JoVE submission site
2. Fax the document to +1.866.381.2236
3. Mail the document to JoVE / Attn: JoVE Editorial / 1 Alewife Center #200 / Cambridge, MA 02140

Dear Drs. Dsouza and Troyer,

Thank you for the useful and detailed comment to our original draft. We were happy to hear that both Reviewers agree with the timeliness and usefulness of publishing a protocol for ChIPseq optimized towards the use for brown adipose tissue studies. In addition to proofreading the manuscript and checking for correct use of metric units and abbreviations, we have now edited the manuscript in response to both the Editorial and Reviewers' comments as detailed below. Please let us know if there is anything else we should edit/improve upon. We look forward to working with you towards a final written and filmed version of the manuscript.

With our best regards,

Valentina Perissi and colleagues

Editorial Comments:

- Please take this opportunity to thoroughly proofread the manuscript to ensure that there are no spelling or grammatical errors.
- **Introduction:** Please expand your Introduction to include the following: The advantages over alternative techniques with applicable references to previous studies; Description of the context of the technique in the wider body of literature; Information that can help readers to determine if the method is appropriate for their application.

Introduction has been edited according to these guidelines.

- **Protocol Detail:** Please note that your protocol will be used to generate the script for the video, and must contain everything that you would like shown in the video. **Please add more specific details (e.g. button clicks for software actions, numerical values for settings, etc) to your protocol steps.** There should be enough detail in each step to supplement the actions seen in the video so that viewers can easily replicate the protocol. Some examples:
1) 1.1: What is the source of the BAT? How was it extracted? Please add a note with a reference to mention this. What is the size/weight of 1 BAT pad?

- 2) 1.4: What is the composition of the lysis buffer?
- 3) 1.5: Mention sonication frequency and amplitude.
- 4) 1.5: What is the composition of the ChI dilution buffer? What is the V/cm for the electrophoresis? Mention gel%.
- 5) 1.7: Which antibody? Mention concentration.
- 6) Convert all centrifuge speeds to g (e.g. in 1.4, 1.5, 2.2, 2.3).
- 7) 2.2: Please reference Table 1.
- 8) Please apply the above ideas to add additional missing details to sections 3-6.

Thanks for all these useful suggestions that have now been incorporated in the revised manuscript.

• **Protocol Highlight:** Please highlight ~2.5 pages or less of text (which includes headings and spaces) in yellow, to identify which steps should be visualized to tell the most cohesive story of your protocol steps.

- 1) The highlighting must include all relevant details that are required to perform the step. For example, if step 2.5 is highlighted for filming and the details of how to perform the step are given in steps 2.5.1 and 2.5.2, then the sub-steps where the details are provided must be included in the highlighting.
- 2) The highlighted steps should form a cohesive narrative, that is, there must be a logical flow from one highlighted step to the next.
- 3) Please highlight complete sentences (not parts of sentences). Include sub-headings and spaces when calculating the final highlighted length.
- 4) Notes cannot be filmed and should be excluded from highlighting.
- 5) Please bear in mind that software steps without a graphical user interface/calculations/command line scripting (such as section 6) cannot be filmed. Please exclude section 6 from your highlights.

Text has been highlighted in the revised manuscript

• **Discussion:** JoVE articles are focused on the methods and the protocol, thus the discussion should be similarly focused. Please ensure that the discussion covers the following in detail: modifications and troubleshooting, limitations of the technique, significance with respect to existing methods, future applications and critical steps within the protocol.

Discussion has been edited according to these guidelines.

- **Figure/Table Legends:**

- 1) Please expand the legends to adequately describe the figures/tables. Each figure or table must have an accompanying legend including a short title, followed by a short description of each panel and/or a general description.
- 2) Please remove the figure/table legends from the figure files and place them directly below the Representative Results text.

Figure/Legends have been edited according to these guidelines.

- **Commercial Language:** JoVE is unable to publish manuscripts containing commercial sounding language, including trademark or registered trademark symbols (TM/R) and the mention of company brand names before an instrument or reagent. Examples of commercial sounding language in your manuscript are Advence Stainless Balls, Advence Bullet Blender, Diagenode Bioraptor Sonicator, Diagenode, Durapore, SYBR, Illumina

- 1) Please use MS Word's find function (Ctrl+F), to locate and replace all commercial sounding language in your manuscript with generic names that are not company-specific. All commercial products should be sufficiently referenced in the table of materials/reagents. You may use the generic term followed by "(see table of materials)" to draw the readers' attention to specific commercial names.
- 2) Please also check Figure 2.

We have removed the commercial language from the text. For clarity we have left in the text the catalog numbers of specific reagents used as requested by one of the Reviewers. If needed, those as well can be removed as they are also included in the updated Table of Materials

- **Table of Materials:** Please revise the table of the essential supplies, reagents, and equipment. The table should include the name, company, and catalog number of all relevant materials/software in separate columns in an xls/xlsx file. Please include items such as sonicator, buffers, antibodies, etc.

Table of Materials has been edited according to these guidelines.

- Please define all abbreviations at first use.

- Please use standard abbreviations and symbols for SI Units such as μL , mL, L, etc., and abbreviations for non-SI units such as h, min, s for time units. Please use a single space between the numerical value and unit.

- If your figures and tables are original and not published previously or you have already obtained figure permissions, please ignore this comment. If you are re-using figures from a previous publication, you must obtain explicit permission to re-use the figure from the previous publisher (this can be in the form of a letter from an editor or a link to the editorial policies that allows you to re-publish the figure). Please upload the text of the re-print permission (may be copied and pasted from an email/website) as a Word document to the Editorial Manager site in the "Supplemental files (as requested by JoVE)" section. Please also cite the figure appropriately in the figure legend, i.e. "This figure has been modified from [citation]."

Figure 2 and 3 are original. Figure 1 is adapted from Cardamone et al., Molecular Cell, 2018. As stated in the CellPress editorial policies webpage (<https://www.cell.com/trends/editorial-policies>) authors' rights include "Prepare other derivative works that extend the article into book-length form or otherwise re-use portions or excerpts in other works, with full acknowledgment of its original publication in the journal".

Comments from Peer-Reviewers:

Reviewer #1:

Manuscript Summary:

This manuscript described a protocol to perform ChIP-seq from Brown Adipose Tissue (BAT) isolated from mouse. There is no doubt that this protocol was suitable to map both histone modifications and non-histone profiles.

Major Concerns:

1. In figure 1, while it was expected to see the decrease of GPS2 binding on the known target, but I was confused by the increases of both PolII (usually active mark) and H3K9me3 (usually repressive mark), could the authors explain more about this?

We agree this was an unexpected finding. We fear that discussing the results of that specific study here would detract from the general focus on the technique per se. To address the Reviewer's comment and potentially other readers' questions about these findings we have now referred to the original manuscript where we discuss at length the accumulation of inactive POL2 on repressed promoters.

2. I almost don't see any catalog# in here, the authors should include them to all the reagents (e.g. antibody).

Thanks for pointing this out. We have now included catalog# for all reagents used.

3. It would be better to have time frames for the experiments, and important notes & warnings for certain details.

We agree it was important to include information about time frames for the different steps of the protocol, which we have now included.

Minor Concerns:

1. Line 23, the authors mentioned that "Commonly used in ChIP assays are samples derived from in vitro cell culture of immortalized cell...", actually there are tons of ChIP-seq paper for the in vivo studies.

We apologize for the misunderstanding, we were specifically referring to mechanistic studies in the brown adipose tissue. We have now edited the text accordingly.

2. Line 91 & line 140, used 50ul in 1000ul lysates as an input was too high, especially the authors used this to make the standard curve with 1/10, 1/100 and 1/1000 (better to have at least 1/5000).

Thanks for pointing this out as a source of possible misunderstanding. We have now clarified that we keep 1% of the lysates as input. Performing 3 ChIPs from each BAT pad means 30ul input from 3000ul lysates not 1000ul. We also commented about the fact that further dilutions might be needed to capture the linear range.

3. Line 147, "4 DNA from ChIP (or input control)" should be "3ul DNA from ChIP (or input control)".

Sorry, it looked like the math was wrong because we had not properly explained that we use 1ul of pre-mixed primers rather than 1ul each. Thanks for pointing this out. We have edited the text to clarify.

4. Line 155, "...If more than one peak is visualized, this is indicative of multiple, non-specific amplicons...", no necessary correct, it depends how the peaks look like, they may indicate uncompleted denature DNA.

This is absolutely correct, we have edited the text to highlight that multiple peaks are problematic and alternative primers should be designed.

5. Y axis in figure 1, usually "Signal relative to input%".

Corrected as suggested in the figure

Reviewer #2:

Manuscript Summary:

The manuscript "Chromatin Immunoprecipitation (ChIP) from Murine Brown Adipose Tissue" of Cardamone et al describes the method for detecting in vivo epigenetic modifications and transcriptional regulators binding in chromatin isolated from brown adipose tissue (BAT). Further, authors describe how to combine the method with qPCR and then next-gen sequencing in order to describe genome-wide chromatin composition in the tissue of interest.

Although ChIP and ChIP-seq methods are present for over a decade in the literature, majority of works and methods describe the use of this extremely useful technology in isolated cells or in immortalized cell lines. It is also very well understood that ChIP on the material isolated directly from the animal/tissue is very challenging and the method has to be optimized for each tissue separately. Therefore, this manuscript describes precisely how ChIP can be performed on adipose tissue.

Major Concerns:

no major concerns were noted

Minor Concerns:

The method is very well described. Scientists are provided stepwise protocol of execution of the technique, including a short discussion of the potential modifications. In fact, in our opinion the discussion is the part that should be expanded. There are several methods of chromatin immunoprecipitation used in the field and this manuscript does not discuss several options that could be used or whether their method has particular advantage in the case of BAT.

Thanks for acknowledging the usefulness of this protocol, we have revised the text accordingly to your suggestions and expanded the discussion about the steps we have optimized to include a justification of the experimental choice made in this regard. We hope this can be helpful if one wants to further optimize or adapt the protocol to similar samples (i.e. other adipose tissue depots or lipid-laden tissues)

In particular:

-Line 94 - authors suggest to use 2ug of the antibody of interest per immunoprecipitation. Although it is very often the case, several antibodies are not quantified by ug. It should be at list mentioned that each specific new antibody amount should be optimized.

Yes, we agree, antibody optimization is a critical component of any ChIP/ChIPseq protocol. We have edited the text to clarify the indication about the amount of antibody and to highlight the need for optimization

-Line 100 - Authors suggest use of Protein A beads slurry. Use of magnetic beads and eventual superiority of authors' method above magnetic beads should be explained. We believe also that as an example catalog number of used beads should be given for readers.

Thanks for this comment, we have included in the Discussion an explanation for this choice.

-Line 114 - Phenol/chloroform extraction is a suggested method of DNA isolation. It should be noted that there are several other methods of DNA extraction available on the marked and why (if it is the case) authors prefers this method above others.

Same as above.

-Line 146-7 - numbers do not add up - $5+1+1+4$ is not 10...

As written in response to Reviewer #1, we apologize for the confusion. It looked like the math was wrong because we had not properly explained that we use 1ul of pre-mixed primers rather than 1ul each. Thanks for pointing this out. We have edited the text to clarify.

ELSEVIER LICENSE TERMS AND CONDITIONS

Aug 15, 2018

This Agreement between Boston University School of Medicine ("You") and Elsevier ("Elsevier") consists of your license details and the terms and conditions provided by Elsevier and Copyright Clearance Center.

License Number	4410291055711
License date	Aug 15, 2018
Licensed Content Publisher	Elsevier
Licensed Content Publication	Molecular Cell
Licensed Content Title	Mitochondrial Retrograde Signaling in Mammals Is Mediated by the Transcriptional Cofactor GPS2 via Direct Mitochondria-to-Nucleus Translocation
Licensed Content Author	Maria Dafne Cardamone,Bogdan Tanasa,Carly T. Cederquist,Jiawen Huang,Kiana Mahdavian,Wenbo Li,Michael G. Rosenfeld,Marc Liesa,Valentina Perissi
Licensed Content Date	Mar 1, 2018
Licensed Content Volume	69
Licensed Content Issue	5
Licensed Content Pages	23
Start Page	757
End Page	772.e7
Type of Use	reuse in a journal/magazine
Requestor type	author of new work
Intended publisher of new work	Other
Portion	figures/tables/illustrations
Number of figures/tables/illustrations	1
Format	both print and electronic
Are you the author of this Elsevier article?	Yes
Will you be translating?	No
Original figure numbers	figure 7.I
Title of the article	Chromatin Immunoprecipitation (ChIP) from Murine Brown Adipose Tissue
Publication new article is in	Journal of Visualized Experiments
Publisher of the new article	Journal of Visualized Experiments
Author of new article	Maria Cardamone
Expected publication date	Sep 2018
Estimated size of new article (number of pages)	10
Requestor Location	Boston University School of Medicine

72 E Concord St
Conte Building K616

BOSTON, MA 02118
United States
Attn: Boston University School of Medicine

Publisher Tax ID 98-0397604

Total 0.00 USD

[Terms and Conditions](#)

INTRODUCTION

1. The publisher for this copyrighted material is Elsevier. By clicking "accept" in connection with completing this licensing transaction, you agree that the following terms and conditions apply to this transaction (along with the Billing and Payment terms and conditions established by Copyright Clearance Center, Inc. ("CCC"), at the time that you opened your Rightslink account and that are available at any time at <http://myaccount.copyright.com>).

GENERAL TERMS

2. Elsevier hereby grants you permission to reproduce the aforementioned material subject to the terms and conditions indicated.

3. Acknowledgement: If any part of the material to be used (for example, figures) has appeared in our publication with credit or acknowledgement to another source, permission must also be sought from that source. If such permission is not obtained then that material may not be included in your publication/copies. Suitable acknowledgement to the source must be made, either as a footnote or in a reference list at the end of your publication, as follows:

"Reprinted from Publication title, Vol /edition number, Author(s), Title of article / title of chapter, Pages No., Copyright (Year), with permission from Elsevier [OR APPLICABLE SOCIETY COPYRIGHT OWNER]." Also Lancet special credit - "Reprinted from The Lancet, Vol. number, Author(s), Title of article, Pages No., Copyright (Year), with permission from Elsevier."

4. Reproduction of this material is confined to the purpose and/or media for which permission is hereby given.

5. Altering/Modifying Material: Not Permitted. However figures and illustrations may be altered/adapted minimally to serve your work. Any other abbreviations, additions, deletions and/or any other alterations shall be made only with prior written authorization of Elsevier Ltd. (Please contact Elsevier at permissions@elsevier.com). No modifications can be made to any Lancet figures/tables and they must be reproduced in full.

6. If the permission fee for the requested use of our material is waived in this instance, please be advised that your future requests for Elsevier materials may attract a fee.

7. Reservation of Rights: Publisher reserves all rights not specifically granted in the combination of (i) the license details provided by you and accepted in the course of this licensing transaction, (ii) these terms and conditions and (iii) CCC's Billing and Payment terms and conditions.

8. License Contingent Upon Payment: While you may exercise the rights licensed immediately upon issuance of the license at the end of the licensing process for the transaction, provided that you have disclosed complete and accurate details of your proposed use, no license is finally effective unless and until full payment is received from you (either by publisher or by CCC) as provided in CCC's Billing and Payment terms and conditions. If full payment is not received on a timely basis, then any license preliminarily granted shall be deemed automatically revoked and shall be void as if never granted. Further, in the event that you breach any of these terms and conditions or any of CCC's Billing and Payment terms and conditions, the license is automatically revoked and shall be void as if never granted. Use of materials as described in a revoked license, as well as any use of the materials beyond the scope of an unrevoked license, may constitute copyright infringement

and publisher reserves the right to take any and all action to protect its copyright in the materials.

9. **Warranties:** Publisher makes no representations or warranties with respect to the licensed material.

10. **Indemnity:** You hereby indemnify and agree to hold harmless publisher and CCC, and their respective officers, directors, employees and agents, from and against any and all claims arising out of your use of the licensed material other than as specifically authorized pursuant to this license.

11. **No Transfer of License:** This license is personal to you and may not be sublicensed, assigned, or transferred by you to any other person without publisher's written permission.

12. **No Amendment Except in Writing:** This license may not be amended except in a writing signed by both parties (or, in the case of publisher, by CCC on publisher's behalf).

13. **Objection to Contrary Terms:** Publisher hereby objects to any terms contained in any purchase order, acknowledgment, check endorsement or other writing prepared by you, which terms are inconsistent with these terms and conditions or CCC's Billing and Payment terms and conditions. These terms and conditions, together with CCC's Billing and Payment terms and conditions (which are incorporated herein), comprise the entire agreement between you and publisher (and CCC) concerning this licensing transaction. In the event of any conflict between your obligations established by these terms and conditions and those established by CCC's Billing and Payment terms and conditions, these terms and conditions shall control.

14. **Revocation:** Elsevier or Copyright Clearance Center may deny the permissions described in this License at their sole discretion, for any reason or no reason, with a full refund payable to you. Notice of such denial will be made using the contact information provided by you. Failure to receive such notice will not alter or invalidate the denial. In no event will Elsevier or Copyright Clearance Center be responsible or liable for any costs, expenses or damage incurred by you as a result of a denial of your permission request, other than a refund of the amount(s) paid by you to Elsevier and/or Copyright Clearance Center for denied permissions.

LIMITED LICENSE

The following terms and conditions apply only to specific license types:

15. **Translation:** This permission is granted for non-exclusive world **English** rights only unless your license was granted for translation rights. If you licensed translation rights you may only translate this content into the languages you requested. A professional translator must perform all translations and reproduce the content word for word preserving the integrity of the article.

16. **Posting licensed content on any Website:** The following terms and conditions apply as follows: Licensing material from an Elsevier journal: All content posted to the web site must maintain the copyright information line on the bottom of each image; A hyper-text must be included to the Homepage of the journal from which you are licensing at <http://www.sciencedirect.com/science/journal/xxxxx> or the Elsevier homepage for books at <http://www.elsevier.com>; Central Storage: This license does not include permission for a scanned version of the material to be stored in a central repository such as that provided by Heron/XanEdu.

Licensing material from an Elsevier book: A hyper-text link must be included to the Elsevier homepage at <http://www.elsevier.com>. All content posted to the web site must maintain the copyright information line on the bottom of each image.

Posting licensed content on Electronic reserve: In addition to the above the following clauses are applicable: The web site must be password-protected and made available only to bona fide students registered on a relevant course. This permission is granted for 1 year only. You may obtain a new license for future website posting.

17. **For journal authors:** the following clauses are applicable in addition to the above:

Preprints:

A preprint is an author's own write-up of research results and analysis, it has not been peer-reviewed, nor has it had any other value added to it by a publisher (such as formatting, copyright, technical enhancement etc.).

Authors can share their preprints anywhere at any time. Preprints should not be added to or enhanced in any way in order to appear more like, or to substitute for, the final versions of articles however authors can update their preprints on arXiv or RePEc with their Accepted Author Manuscript (see below).

If accepted for publication, we encourage authors to link from the preprint to their formal publication via its DOI. Millions of researchers have access to the formal publications on ScienceDirect, and so links will help users to find, access, cite and use the best available version. Please note that Cell Press, The Lancet and some society-owned have different preprint policies. Information on these policies is available on the journal homepage.

Accepted Author Manuscripts: An accepted author manuscript is the manuscript of an article that has been accepted for publication and which typically includes author-incorporated changes suggested during submission, peer review and editor-author communications.

Authors can share their accepted author manuscript:

- immediately
 - via their non-commercial person homepage or blog
 - by updating a preprint in arXiv or RePEc with the accepted manuscript
 - via their research institute or institutional repository for internal institutional uses or as part of an invitation-only research collaboration work-group
 - directly by providing copies to their students or to research collaborators for their personal use
 - for private scholarly sharing as part of an invitation-only work group on commercial sites with which Elsevier has an agreement
- After the embargo period
 - via non-commercial hosting platforms such as their institutional repository
 - via commercial sites with which Elsevier has an agreement

In all cases accepted manuscripts should:

- link to the formal publication via its DOI
- bear a CC-BY-NC-ND license - this is easy to do
- if aggregated with other manuscripts, for example in a repository or other site, be shared in alignment with our hosting policy not be added to or enhanced in any way to appear more like, or to substitute for, the published journal article.

Published journal article (JPA): A published journal article (PJA) is the definitive final record of published research that appears or will appear in the journal and embodies all value-adding publishing activities including peer review co-ordination, copy-editing, formatting, (if relevant) pagination and online enrichment.

Policies for sharing publishing journal articles differ for subscription and gold open access articles:

Subscription Articles: If you are an author, please share a link to your article rather than the full-text. Millions of researchers have access to the formal publications on ScienceDirect, and so links will help your users to find, access, cite, and use the best available version. Theses and dissertations which contain embedded PJAs as part of the formal submission can be posted publicly by the awarding institution with DOI links back to the formal publications on ScienceDirect.

If you are affiliated with a library that subscribes to ScienceDirect you have additional private sharing rights for others' research accessed under that agreement. This includes use

for classroom teaching and internal training at the institution (including use in course packs and courseware programs), and inclusion of the article for grant funding purposes.

Gold Open Access Articles: May be shared according to the author-selected end-user license and should contain a [CrossMark logo](#), the end user license, and a DOI link to the formal publication on ScienceDirect.

Please refer to Elsevier's [posting policy](#) for further information.

18. **For book authors** the following clauses are applicable in addition to the above:

Authors are permitted to place a brief summary of their work online only. You are not allowed to download and post the published electronic version of your chapter, nor may you scan the printed edition to create an electronic version. **Posting to a repository:** Authors are permitted to post a summary of their chapter only in their institution's repository.

19. **Thesis/Dissertation:** If your license is for use in a thesis/dissertation your thesis may be submitted to your institution in either print or electronic form. Should your thesis be published commercially, please reapply for permission. These requirements include permission for the Library and Archives of Canada to supply single copies, on demand, of the complete thesis and include permission for Proquest/UMI to supply single copies, on demand, of the complete thesis. Should your thesis be published commercially, please reapply for permission. Theses and dissertations which contain embedded PJAs as part of the formal submission can be posted publicly by the awarding institution with DOI links back to the formal publications on ScienceDirect.

Elsevier Open Access Terms and Conditions

You can publish open access with Elsevier in hundreds of open access journals or in nearly 2000 established subscription journals that support open access publishing. Permitted third party re-use of these open access articles is defined by the author's choice of Creative Commons user license. See our [open access license policy](#) for more information.

Terms & Conditions applicable to all Open Access articles published with Elsevier:

Any reuse of the article must not represent the author as endorsing the adaptation of the article nor should the article be modified in such a way as to damage the author's honour or reputation. If any changes have been made, such changes must be clearly indicated.

The author(s) must be appropriately credited and we ask that you include the end user license and a DOI link to the formal publication on ScienceDirect.

If any part of the material to be used (for example, figures) has appeared in our publication with credit or acknowledgement to another source it is the responsibility of the user to ensure their reuse complies with the terms and conditions determined by the rights holder.

Additional Terms & Conditions applicable to each Creative Commons user license:

CC BY: The CC-BY license allows users to copy, to create extracts, abstracts and new works from the Article, to alter and revise the Article and to make commercial use of the Article (including reuse and/or resale of the Article by commercial entities), provided the user gives appropriate credit (with a link to the formal publication through the relevant DOI), provides a link to the license, indicates if changes were made and the licensor is not represented as endorsing the use made of the work. The full details of the license are available at <http://creativecommons.org/licenses/by/4.0>.

CC BY NC SA: The CC BY-NC-SA license allows users to copy, to create extracts, abstracts and new works from the Article, to alter and revise the Article, provided this is not done for commercial purposes, and that the user gives appropriate credit (with a link to the formal publication through the relevant DOI), provides a link to the license, indicates if changes were made and the licensor is not represented as endorsing the use made of the work. Further, any new works must be made available on the same conditions. The full details of the license are available at <http://creativecommons.org/licenses/by-nc-sa/4.0>.

CC BY NC ND: The CC BY-NC-ND license allows users to copy and distribute the Article, provided this is not done for commercial purposes and further does not permit distribution of the Article if it is changed or edited in any way, and provided the user gives appropriate credit (with a link to the formal publication through the relevant DOI), provides a link to the

license, and that the licensor is not represented as endorsing the use made of the work. The full details of the license are available at <http://creativecommons.org/licenses/by-nc-nd/4.0>. Any commercial reuse of Open Access articles published with a CC BY NC SA or CC BY NC ND license requires permission from Elsevier and will be subject to a fee. Commercial reuse includes:

- Associating advertising with the full text of the Article
- Charging fees for document delivery or access
- Article aggregation
- Systematic distribution via e-mail lists or share buttons

Posting or linking by commercial companies for use by customers of those companies.

20. Other Conditions:

v1.9

Questions? customercare@copyright.com or +1-855-239-3415 (toll free in the US) or +1-978-646-2777.
